News

By Cormac Sheridan, Staff Writer – Published by BioWorld™ – The coming months represent a crucial phase in the development of Selection Inc., a U.S.-German firm that is tackling a…

Ongoing phase 1b trial is designed to evaluate safety, tolerability, and efficacy of si-544 in T-cell mediated autoimmunity Dosing of MAD stage has been initiated; first results expected for late…

Phase 1b trial is designed to evaluate safety, tolerability, and efficacy of potent Kv1.3 blocker in T-cell mediated autoimmunity – San Diego, CA, USA, and Munich, Germany – September 12,…

Novel ion channel blocker designed to combine high efficacy and durable response while maintaining full immune system functionality – San Diego, CA, USA, and Munich, Germany – May 09, 2022…

si-544, a Kv1.3 blocker with class leading selectivity and excellent preclinical safety profile, scheduled to advance towards clinical development in early 2021 SAN DIEGO, September 16, 2020 – selectION, Inc.…

SAN DIEGO, May 31, 2019 – selectION, Inc., a biotherapeutic company focused on the development of peptide ion channel blockers with class leading selectivity, announced today it has received a…

SAN DIEGO, November 30, 2018 – selectION, Inc. a biotechnology company that has established an efficient technology platform to develop novel peptide therapies incorporating highly selective peptide blockers for ion…

SAN DIEGO, August 29, 2018 – selectION, Inc. a biotechnology company that has established an efficient technology platform to develop novel peptide therapies incorporating highly selective peptide blockers for ion…

Dr. Schuh has over 20 years of executive leadership experience in the biotechnology, healthcare and life sciences industries and has served as CEO of five life sciences companies, including Arcturus…